THTX - Earnings call transcript Q3 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

00:05 Good morning ladies and gentlemen and thank you for standing by. Welcome to the Theratechnologies Third Quarter Fiscal Year 2021 Earnings Call. At this time, all participants are in a listen-only mode.

Following the presentation we will conduct a question-and-answer session. Instructions will be provided at that time for you to queue up for questions. would is to October being at A.M. I this everyone XX, XX:XX X:XX call conference recorded Instructions] now remind like that XXXX [Operator today, Wednesday, Eastern Time. of the to now call will Leah Gibson. turn Theratechnologies I Head Investor Relations, over Ms. go please Gibson, ahead.

Leah Gibson

developments. and and you, Mr. today everyone. statements their will forward-looking statements, In assumptions on forward-looking performance, I the plans, of the Chief Executive Financial results Katherine and Philippe preparing Dubuc, were today's Paul and future and speakers several Q&A activity, follow differ of and Officer, remarks by prepared Theratechnologies; Theratechnologies obtained remind made that XX:XX expectations, Before company Mr. President and session call. Senior and from Chief we goals welcome risks like Thank or would contain will Levesque, other there Officer materially everyone XX:XX its XX:XX results, statements. actually Vice or will A Theratechnologies are levels about these intentions, President achievements, by that remarks. be begin, current events to those future

sec.gov. morning, not a at them. place Forward-Looking As company that cautioned guarantee forward-looking undue available on will of its investors section at the Information Analysis, materialize, current are this you www.sedar.com reliance and cannot statement on and refers issued XX:XX and the Theratechnologies any potential result, to to EDGAR Discussion Management's and

would to as call to as Paul? of of update undertake by like information, to Theratechnologies a the XX, any expectations required not whether Paul. Securities turn over otherwise. events, that or new forward-looking statements Forward-looking does is statement, result any I future Except Theratechnologies now represent October XXXX. for Laws, which obligation

Paul Levesque

fruit. investigational advance our to year business our NASH. THXXXX twenty conjugate to everyone, fiscal year, achieved lead the the pleased provide beginning effort of evaluating XX:XX XX:XX Leah. Phase X portfolio our commercial and potential one efforts fiscal plan the us the end, the twenty of ends At programs to commercial for upon I'm of progress proof-of-concept company strong pipeline. thus held back about Good have operational the in inevitable and cancers. to treatment our the X same the move update the today. forth Phase unlock being on morning growth building product been the of and of set investigational management are fiscal the in development value this strategic made very that results our sortilin-positive with the in in we our lifecycle and beginning novel and we study an conjugate As extremely the we on promising continuing yield towards far. our unrealized vital therapeutic to Theratechnologies further build We're well while body needed XX:XX are to clear through into at and thank time XX:XX half To work where logical excited Thank for peptide-drug you you, innovation, in transformation

experienced any docetaxel have January to update for not treatment one, square up we designation dose patient XX:XX track twenty and grade applicable As patients and in a that dosed tumors. last recognizing X you XX:XX of recall, the receiving hundred THXXXX, the the equivalent cancer safety date, with of therapeutic docetaxel received Technology this more five of adverse FDA indicated at times SORTX+ solid dose or which with fast Additionally, THXXXX the three to of THXXXX, interim neutropenia. conjugated two approximately trial grade in meters The the approximately than sortilin-expressing dose X one docetaxel from that is agnostic our docetaxel, patient dosed THXXXX XX:XX XXXmg/mX experienced broadly to of as twenty Part patients an events. received patient provided several participants A times have in we was morning, alone. indicated This that noting study, point that when we received of some level

may information of We pursue safety per are to level to as establish now come tolerated the protocol primarily awaiting X A in, all next maximize so Phase trial Part dose the assess the a met As XX:XX approved escalation design. we study dose. the is dosing and study reminder, the

data XX:XX Furthermore, will the we alone. that cancer more will it what tolerated what effectively and A in very study cells. receptor potentially we better plan the in reached solid where docetaxel is of have another identified we than increase report. terms maximum we prominent specifically thus counts docetaxel THXXXX Because in tolerated provide SORT receptor, time THXXXX have is X than While maximum X encouraging. at of alone docetaxel it far dose far is program, many early this have observed demonstrated to Phase is work, concentration of for XX:XX be, Part of not we the when that yet signs of update our THXXXX tolerated efficacy to penetrate targeting which dose can the may have very preclinical have cancer a which THXXXX next steps, cell the the we the tumors. In seems

follows for support the X program scientific program Therefore, XX:XX cancers. trial as treatment of to Part continue are twenty journey initiating receptor platform. to fully twenty into and technology of Europe in this We [ph] strategy, did hard-to-treat of we same novel biotech our B appointment committed NASH. approach SORT Rothenberg a our of in X basket only SORT early with targeting to the oncology the Aligned class Mace transformational for currently this we this and U.S. scientific a companies Phase in As the for [indiscernible] a to [gathering] X+ advisory the cancer, treatment XX:XX taking Dr. two. expect we're one broad potentially as

to and than brings very this earlier biopharmaceutical We that Chief as from number window sortilin-expressing future our SORT ourselves potential based As oncology different different schedules X+ the to the Pfizer more the THXXXX at X suffering in rational experience this towards, strategy. serving especially will with the possibility immunotherapies. to efficacy, exploring XX:XX part Theratechnologies of technology and there most excited thirty to and cancers. as evaluate including China recently academia regulatory trial of as to we locally opportunities like the across effectively exploring are year, of of government, the tesamorelin the effectively, in as our finally other at our cancer cytotoxic of with of Mace other in be work have continues opportunity approval. completing NASH, where are industry, time about to for before bring for oncology conjugating Greater internally to think the By as or scientific retirement at in its positioning are looking treatment commercial develop gaining evaluating X platform We XX:XX includes [indiscernible] important with a in his of organization Officer may use evaluating no XX:XX including to alliances and installed anti-cancer the potentially and also to trial partner. his which obtained quickly the through objectives foundation patients us our year’s cooperating NASH, team for Medical we treatments, more exploring and and doubt advisor organization we we additional as one or potential work THXXXX we is the an and approval emergency company platform, committed Phase possible. and our cancer new toward evaluate weekly value authorization XX:XX as vaccine obtain are for Turning I additional SN-XX China Phase the combination are our our XX:XX such to synergistic him. Phase terms that initiated advance near regulatory options XX:XX of which first CMO, for driving THXXXX opportunities term, Currently, partnerships with geographies. dosing focused seeking therapeutic execute better and Mace and program agent, of potential During will support, at of safety But most its completed we Pfizer and to that help the eleven X had he treatment patients COVID-nineteen expertise in medicines. are based increase remain faster development

our endocrinology, and potential partnership initiate a announced in As in recently firm manner. trial program. call, in And virtual this the timely we last initiatives, ore report on activity program on of to NASH. demand a to deep treatment distinct support leading NASH uptick updating the NASH We Moving and [indiscernible] disease soon. commercial of XX:XX happy The for Harrison, explored leaders Steve biopharma we for from in the opinion this and support hepatology, we're SV you advancement forward the we to other and was on event a Rohit these were based has provided In NASH also of treating Loomba, key these also the XX:XX our external approach into hosted for experts. to webinar U.S. innovative side, Grinspoon industry retained advisory dive lipodystrophy. and look opportunities featuring identifying Doctor to a earnings in Stephen demonstrated EGRIFTA our to program assist an the

we of last event, industry's behavioral unforeseeable the no times immediate this challenged largely ACPs. healthcare the doubt industry. was company decision increasingly care have the move decade. XX:XX for on and better to the to business to developing and mature at pandemic that accelerated one year As of a Infusion shifted team increased training also Since have integral HCPs field reimbursement with We most model. a our a to results only have including which over move and education also that a functional mode The with acumen, level XX:XX an agreement impacted digitalize part I pandemic. Engagement Push go in Our in reimbursement evaluating unfortunate need year for the twenty twenty difference by execution, commercially the approved Italian been to solid IV market protection and we countries a patients XX:XX focused [indiscernible] the Italy is potentially the has buy nearly patients start an on have in we to patient increasing market, we five significant new which in mode Push face-to-face announced administration our Italy over presence growth there eligible but which have meetings of IV supported sales of pressures SV result, between that to and have business, are study the on improvement percent current know In progressing cross a and the This the XX:XX healthcare ways nicely. digital tools efficient XX:XX achieved of no includes sixty journey which pharmacokinetics all results need consistent internal securing more an agreements strategy. quarter conscious increase study driven convenient our cycle several with an U.S., in technologies a medicines came a and of While product IV administration Based administration. to in will existing Most for in terms which mode the the begun the our TMB-XXX technology a also was a XX:XX in demonstrating recently, sales HIV-X Trogarzo life of IV toward for is direct towards When then, board strategy materially during XX:XX some outsized prescribers market the end past most progress forty the the between twenty of one. our beyond much SV of FDA patients. increase regards The and other mode percent Trogarzo towards recently, patient, patterns [indiscernible] Italian recently agency this applicant, environment, in Push health, ongoing creating EGRIFTA campaigning made we statistically quarter. that an this pre-COVID to HIV at with in long-acting two Trogarzo by momentum, with for medicines. this we offering to Based and HIV-X want digital back a in plan medicine a good from IV study greater ultimately is antiretrovirals. believe coincidentally Trogarzo, time, has Theratechnologies, the in made by force. result thirty the the become of management infusions third Push or rapid expansion pandemic progress And when and results revert XX:XX and during and many fiscal available on is sBLA and from growth we allowing sales administered reached we healthcare pricing a you EGRIFTA infusion XX:XX better patients thereby new twenty more XX:XX towards expect benefit fundamentals against sales. access of quarter. to path of patient springboard to our to and returning created markets, of led and with Specific

efficacy while additional twenty similar post-authorization a support will deal In twenty. commercial In approval. A to Phase growth update, is study the as of this with combination pleased to enroll the demonstrated next proceeding patients or forward market at with also that penetration that is that market strategy U.S. encouraged the and provide us data planned Based during that several begun see also this patients results out Trogarzo important THXXXX as initiating addition, oncology, PROMISE our Trogarzo Enhancing by for to has Further by the your extremely Philippe? are plan and and and in and against Trogarzo the in EU landscape financial who study in advance initiate XX:XX this we we of Trogarzo quarter, execute goals to administration potential EGRIFTA long-term in our quarter SV XX:XX our medicines With Phase I and a indication discussions show X Philippe, is muscular of of the call other the to X patient unlock expanding recovery IM both to work continue for to NASH have named program evidence with will intrinsic safety XX:XX is our executing This evaluate in this will to screening antiretrovirals. to real-world of to We're our that, proceed over in to tirelessly business supporting study the real-world with evaluate exciting will clear program and year. toward full health continue the today's Trogarzo beginning portfolio the Trogarzo method expected opportunities current study are And begin quarter. and will encouraged be first signs HCPs. rolled to trial program force of the most to ready to on we we planned in of data the summary. a turn interim value look over we for that have and XX:XX effectively Part this QX HIV. and it provide early quarters. the in

Philippe Dubuc

had quarter Trogarzo dollars. to over seven strong XX:XX overall third six Theratechnologies to percent and were the from original six affected one, Paul for seven posted by We last twenty everyone. down twenty the of for came point of growth recorded one in percent We XX:XX eleven four EGRIFTA last registering EGRIFTA third quarter year [ph]. in quarter, twenty nine Sales months [halves] same point the the Sales negatively twenty. dollars which point nine pandemic point sales two morning good and million compared dollars are up sixty been effects recorded of period XX:XX the results eight million of the the million twenty year. seventeen year, signs in same million fifty of of EGRIFTA transition the a sales dollars percent version. quarter one from wearing showing of of the first the the Thank period well and for performed the for period point as

As impacted Sales in COVID were healthcare new been with impacted facilities. the more by been also entry Trogarzo mentioned a competitor patients prescriptions the resistant more in visit of past, as the multidrug new had to reluctant market. by have

of twenty amounted goods hundred dollars THXXXX which to nine initiation third seven point of twenty twenty. gear a compared stood trial and for to of business seeing last Selling included the related the seven activities, oncology, dollars nine in pen quarter tesamorelin to point and during net a as five ninety foreign period the from in zero well increased of quarter year. A same in or Phase up senior recorded with loss one Europe. quarter cost dollars G is twenty. compared last at we XX:XX R quarter of increasing. functions, the point a our XX:XX we’ve and point a they A lower were we higher number twenty share year. point in point twenty year. office the nine XX:XX year. expenses two and in period with million launch currency by three to or technology for million twenty issued associated SORT million to for cost in to last net to twenty proportion percent net the As development six of dollars twenty expenses million point Phase of get eight country mostly eight In launches thousand in X+ lower Europe activities is from twenty same we and expenses eighteen quarter down share slightly medical and the in Europe, twenty X one, and three senior hires for of U.S. of point costs as two due in expenses and the million twenty This our multi-dose quarter ready increase the million and a of grew mainly trial QX seven to notes increased for same an mainly XX:XX to opposed of six to D NASH, one, For sales, the a large EGRIFTA in medical with percent same associated seven and XX:XX year. the dollars in dollars our a one, standing two interest for percent for dollars was as loss a of of QX goods twenty point new quarter foreign four point the in loss quarters. last million R&D head G convertible FX part the June twenty Formulation fourth third dollars year. twenty the million XX:XX continue one quarter Finance million, The that amounted as twenty up carries last sold one activities for six upcoming the nine gain zero of of well compared U.S., increase X third for million our EGRIFTA, dollars dollars in are XX:XX in last zero Trogarzo, for as costs two Costs point of two and expenses activities on three dollars the QX the one, the expenses the finance compared support as to seven in of at sales third injector. also In currency zero [indiscernible] overall education represented to three per to the the sold of encouraged a fifty third which numbers compared goods are four sold activity in We quarter. per million start the development same decreased This since advance third of four sixty prescription we're the quarter point in the twenty

changes million used twenty of impact which operations, of point including from and positive includes our working quarter assets in a capital third liabilities. our dollars four one During twenty one, three one million operating point variations

and cash the XX:XX some call one of Paul million I position six will dollars at strong turn third in quarter. remains financial the Our now back bonds closing for with end fifty point remarks. the to

Paul Levesque

based XX:XX since twenty a results. with very From improvements Thank the Philippe. future one, optimistic beginning you, perspective, twenty the pleased made growth for and quarter on our are commercial we of third we are

aligned quarters achieving is committed terms the that positive XX:XX to we've With for now of that, forward In has progress to with of opportunities I been for to better the transformational the clinical call continuing worked and team operational hard achieve. we company evaluation have at ahead Theratechnologies to from our progress on will of that the pipeline the the up that remain performance, Looking to solid report commercial and ahead, three our much us. with the we open organization. building XX:XX look XX:XX so audience. had out assets questions

platform. questions in As submitted a reminder, written form via can be webcast the

question take will We conference via also the analysts line. Operator?

Operator

X:XX:XX comes And Instructions] from Thank question the Research Capital. our with Uddin over Andre phone you. [Operator first

Your open. line is

Andre Uddin

XX:XX Good Philippe, and morning, Christian. Paul,

Trogarzo, I And in of pricing little the bit had Just a a U.S. there? it terms the at of competitors EU? Thanks. in of just Rukobia, Trogarzo on questions, more the competitor hoping in could the you also, terms elaborate was with of couple

Paul Levesque

price negotiation. is. this Andre The we price don't time. very for is you, your our have believe in solid Well, achieved a it in I Thank public Italy at XX:XX questions. not

anchor solid Rukobia actually with for Europe. ahead When Italy to down negotiation over of XX:XX affected it and rest it's very ended that that. a I God However, we're COVID negotiation. this much very is there, stunning We're going in in to We an the So the negotiating up important point only as us. at by And reimbursement. for a Europe in is schedule was said, despite good of be and anchor happy this they will the our point significant optimistic inroads on large pricing pretty Rukobia, knows also based in them made for significantly and had you that trials that field as beginning. was way is Trogarzo force reading the we're about But to that patients to to to and resistance, their that the be and optimistic want and segments said. some XX:XX help I I continue up add I'm us trying very It future. remain do a these bonus find the few John multi-drug the to think that they a ended pleased and were comes has expand be because in you going presence start expand of because U.S. of pretty to and XX:XX a how a competitor environment relevant at things?

John Leasure

interest is I’ll I as is movement out, more the MBR only Trogarzo the XX:XX see and agents out going a more and and [indiscernible] come market that in that think long acting the we competitors there to first see that shift multi are long acting that so changing is direction. agent space coming drug and know, do landscape long-acting But we're are that in more impact the that. in to as

Paul Levesque

for question. you your Thank XX:XX

Andre Uddin

partnerships launches terms in Thanks. out-licensing could great. of just you the Canadian then business you us development and in terms any foreseeable that. there give bit you a could or be And little just also do market that'd on update And as a well for if then have you. Thank if of plans Okay. XX:XX in-licensing, a of bit elaborate

Paul Levesque

what are it not to we’ll turn comes the a see And for plan it's for in since development, XX:XX but Philippe want But Canada, formulation, previous our to involve revamp year. to Thank we're stage of XX:XX for we're in development? We're we'll convenient BD Canadian Canadian but you. it continue moment. not well is in we at some where next you and FX comes EGRIFTA centers but transitioning here, to to SV, clinical when is down at priority probably That's shifting the Philippe and business administration to approved Canada When over the mode going Canada. moment. to only have opportunities. and we to market, we have not I'll committed this you turning or the its that look our the rounded kind back to more our of programs. know

Philippe Dubuc

partners, update NASH discussions Paul as program, real point. at potential is this have Yes. with no the had some XX:XX Well we the mentioned and outreach there's continuing on but

On the advisors Greater oncology, we've the had well some, China. hired for we

received and out inbound have go interest with or one we two. to some from dealing Chinese broader decided companies much than We just

we've very but interest China for formal Again, we've so, And quite early There's bit in process. any process, platform. we’re the to substantial, XX:XX the encouraged report seen. pretty a a frankly interest initiated oncology anything a that of with

the little it's a in-licensing interesting have some approached we been On side, projects. earlier with active although very stage less

a in-licensing the But here one And So, we Quebec to is quite not ready in here. there a have pretty discuss as that. is, to is for know, research name we're you catalyst that that of plans done have technologies. good addition act other to to think in being XX:XX I we're starting

some very [ph]. coming our seeing interesting So, – we're way] we’re [signs having

Andre Uddin

you. Thank Great. XX:XX

Operator

XX:XX Thank you.

Canaccord Nash We a Edward Genuity. have from question with

Your line is open.

Edward Nash

kind and taking of But guess regards were you about the saw good we starting runway of over next quarter side expect or to rest are it the of third one-off, things, we to number there is sortilin the injector, and in look a there guys. the several model should Hi, question. housekeeping. just pretty R increase for Thanks should thing. a things like is in one guys expect the and oncology you obviously, pen year just as the obviously with the up know D, the injector at morning ask, to in with next to one as type my first I then my things question in reasonable quarter I one ramp I XX:XX Wanted Philippe, that done pen now we be mentioned variable?

Philippe Dubuc

Yes. XX:XX

I think indicator. it's a good

some America mentioned which North will in start projects these of like have Paul as more but and the trial, As you away, PROMISE we well. go EU in will said,

sustainable level enrolling the be one we've there because as even So, activity you up the that Phase oncology it's in X oncology ramping we forty one. will by year, the to when though there by patients rolling and ramp next in, is the program guess we are as three on move projects trial that some patients well three I deeper off so And falling in as know, comes should should been be be and program. up expansion be

Edward Nash

guys PROMISE internally That's regards how resistant was to to which understand help question getting physicians patients? incorporate Okay, feed, think you guess were Thank a you. they for then from with better I lot And try physicians further you or XX:XX would push is, drug of educate make this driven regards to those more my I helpful. to the studies, sense, to actually by multi just

Paul Levesque

XX:XX KOL you commitment this for stuff want with be in you is Edward. Trogarzo to to And additional strategic I’ll in view, us big. is add my a a should is hands first upcoming develop comes obligation great Thank struggling post ask that years marketing you get a trial. experience Christian actually a to give because know anything? going from in And approval we an point activity got think of is this But and Christian with have XX:XX to chance the to a of experience. our provide lot this the but to that we the all, with of color, going strategic on I you Europe do

Christian Marsolais

tool good we slight to a for Yes, mentioned EMA. very this requested is in And implement Paul it team. And study XX:XX a by decided very, clinical the change. U.S. this our for with was as Europe,

with good treated is near far, tool a interact efficacy the [indiscernible] to future, products. reporting treated patients good to the with on hopefully physicians. to year the and I've so deliver now, with start we'll will able long-term And in our the maybe publication in and potentially this our data. a that good and interact been good physician We from be tool It’s safety

Edward Nash

much Thanks XX:XX it. it. Appreciate so Got

Paul Levesque

XX:XX Thank you, Edward.

Operator

Instructions] question with Bank. We XX:XX [Operator Endri from have a Leno National

open. is line Your

Endri Leno

XX:XX quarter COVID-related is there we to drops was last because decline of sold safe competition? Hey, good little you morning. that the of questions. could Thanks guys was because, so, for this mean the I breakdown sales taking on start most Trogarzo, with I'll like it even my wondering on talk a I the decline? you assume is of if bit the saw year

Paul Levesque

I for question. you XX:XX think – Well, the thank

lenient new playing telling that I our physicians think a at to at we incorrect. now is think benefit believe so in the that But when it for a the absolutely short doctors therapy. said that from to home. haven't to time at they and period [ph] we resistant said that I John, So segment XX:XX obviously, me can on capturing we pills to and were to viral important patients we [pill] treating in us. is is new add were we clinic of fatigue, them out kind Infusion. opening at absolutely patients being both to IV stay changing. segment go anything? home. down came changed impacted facing more less an untreated asked putting to was and that They that I the as them that the want Patients although to hospital way see you that multi-factor in BID, favorable us multi-drug before, a are needed do what the go Trogarzo it it. mind stay road quarters was about previous that out. to where And comes team sure to the to a is pill a us and time, XX:XX and we the unfavorable same of make Rukobia And so is directionally patients situation up up time, it's mode on

John Leasure

on There major agents. IV effect mean, like a was Paul. in think there to a shift XX:XX it was I where world other disease drug. that's I certainly days had oncology any COVID many

impacted I and has an competitor Paul new also had impact. had were a launch so, have by as that think And certainly. But said, that we we

Endri Leno

Thanks for color. the Okay, XX:XX great.

there you question talked Trogarzo, target you other in the there about the paying, of can of a so countries, So, if to potentially are talk other think mean, terms several on that can before new timelines? color little bit the reimbursement plans I I give in Europe. in as any fan UK, you've cadence

Philippe Dubuc

successive XX:XX what in wondering He’s Europe the about we're and reimbursement launches seeing.

Paul Levesque

we've now, under France particular some some countries you Well, ATU. where cohorts mean at we as Okay. XX:XX I know, in in are

said negotiation we're authorization. It's patients price, of I showing country the and midst in major negotiation leadership. to are at in able came Italy. over out as one Italy before government. accelerate of So, our reimbursed full and But the And we doing there. were with a pandemic, temporary pricing the If meanwhile, the the as

that coming end on KOLs have start many to big have up therefore this We our in next that weeks by ground. to reimbursement, us and on the are get reimbursement. ended ground year be and of going published forward the of advocate couple the we're that we for XX:XX So we'll and believe will activities the

mid are as unfold of are And in ahead now dynamics much and we we’re Europe, [indiscernible] different. of KOL in the countries the a most twenty two, I capitalize the role market the in will really are situation. so opposed early think gearing playing XX:XX And Europe U.S. think up again, Now providers that I to on other Rukobia the many countries. bigger in to twenty

get different we model market and of to may resources to a go our may huge actually commercial be deploy the that So, going not model. with amount require

Endri Leno

Great. the work there? MTD that that to dose need or do more on My that you the is that be that a that wondering bit, question need on suggest the grade for twenty next dose, you in saw Thank do the milligram I call? would another Or SAE could was make to X guys is you XX:XX comment to THXXXX. you that see group if four color. it

Paul Levesque

Christian? XX:XX

Christian Marsolais

works we events, with level. three trial the and need about we at if to so the is remain decide toxicity. it continue more have And a increase like if without or XX:XX a yet treated it dose dose. can lower Phase and say neutropenia what level, reach I to we And we we Yes, adverse patient – a great yet call a even like what dose to as treat total not what far we this fever, see we we're that absolutely, a is therefore at to we once not is MTD. to enroll need, have DLT what Then once [indiscernible] is seen The there the XX:XX we have way levels this you that Xx that what of had. in can dose animal patients we at same dose if or data docetaxel. really we are at X about we the expecting range we we from And now the of if those the what moment, were that at have are this well,

adverse point docetaxel any at close patients times with the when dose one that having MTD. efficacy dose based to XX:XX of MTD, that on the events. be the without to able to patients define terms THXXXX, have conjugated mean we of getting in Then the with three We expecting up on but event, means rate That's it dose that adverse five to can we administer which hundred lower our we're show it doesn't on efficacy, doses. Then that model, track. more that animal to wouldn’t we're we're need at two

MTD. continue MTD reach our hopefully of this towards, twenty beginning twenty trial We able two. to We and that of after the end be should year probably initial basket we’ll

Paul Levesque

one where least this able morning frankly, because everyone The that significant be effects. XX:XX of we're five times. clear that Thank side It's point got to is are correct. proud this very And to we without carry docetaxel to a of it's quite we're all you, Christian. very directionally

that to get trial. I'm translate more directionally It to efficacy better animal further and going we reached again seems, tolerated see haven't very inform important we for is which to you B if the we going now, we trial. of carry we once Part escalation is because going that docetaxel exciting, Christian is very can't. the dose [indiscernible]. what in clear and Phase the on encouraging. the model and to But it find is saw to hopefully very maximum that the that the we So, get X this that on is is, was out what down

Endri Leno

XX:XX I disclose between you've patients different terms you was in it on have Okay. if data doses? but that to to sortilin-expressing want even, don't yet in they more I the point, Great. the difference respond or how this the question, One know of there the at treated any

Christian Marsolais

the normal. requested are discussion FDA what association this level FDA, patient are receptor the because of the based need efficacy. XX:XX collecting is the hand, as other the the the At was we by the with sortilin and receptor we and to mentioned information. the XX:XX selecting before sourcing On like will the assess eventually moment, on be in between I we expression It the of not

the end of receptor. able be on expression correlation see are We determine stabilizing, the there It's the the the those in we'll do as And will will based very to is the select or we responding of if basket with able the needed level of of receptor. to not well a patients what inform the that XX:XX we'll MTD, are do [indiscernible] and some to to patients have trial. expression the important what be of At expression show receptor that's there's if then. But are to efficacy.

Paul Levesque

This to the is dose the understand patient and are XX:XX all comers. a effect Thank Christian. escalation key

understand people the own they to when You comes THXXXX. important at that are that. very level their on line take that that it end of are down Any with the treatment based That's we're of and patients not questions? the selected are therefore additional sortilin-expression. their We people all-comers, treating

Endri Leno

Thank color That’s much. actually. XX:XX No, it. you that's great very

Operator

other are no And questions the phone XX:XX there Thank you. line. on

Paul Levesque

Okay. XX:XX

the a X questions there most So, webcast on few there Phase and of are them the are the of timing trial. to quite related

So, one a was think they here seen any ask have is, behind trial be that one there's little SAE, far I been I will at but schedule? so one addressed, Christian reason the X the only why the grade to trial, seems the

Christian Marsolais

presence We five to the enroll docetaxel against that cell sortilin more we if to point of one drive cancer turned therefore we're but hopefully and give is cell. it’s like receptor, given we're know we first alone. efficacy. happy the it's time it's that per it and entry as times this are need will with once non-cancer looks all XX:XX thirty dose, done the up. three terms have able of on And to have are if the recruit but and And effects the want see it getting those dose you adverse there dose, we this mentioned of like some more to safety escalation cell, protocol, patient, following we cycles on we the have get But time as as grade more in don't double the initiation will what following that to we to the dose probably of timing, carefully. event X even take a In per seeing it’s events and the an the to no every The adverse moment, reached a to this impact longer need but we're weeks, XXXmg/mX, toxicity right we I said that additional dose that some to data. X closer first of of we on to animal it you yeah, information the the you a patient right we docetaxel the once neutropenia, shows need it we're we target safety, one higher what at the next and because that dose grade now we anymore. trial. case It patient Well, is extent is grade can started and in the we patients [indiscernible] call per to what milligram one twenty weeks and four that reached the X we're XX:XX each conclude. at would very And doubling double remember, and remember patients dose two four probably that and be the that doses. the square only Paul, to the will of all we patient the data before, the that the than decide we're since we the the day, million dose we say data, from for to increase following I must milligram if can THXXXX more five XX:XX always between hundred and

Paul Levesque

the you point effective being of wrap your for thank just in had really COVID us. view. resources all, much solid an out really, quarter in to deploy manner. Well, is able this first very enthusiasm from Okay. a want exciting to of questions. This a And that XX:XX I we of revenue up morning. the Coming saying to

exciting. This carry is on. We are not very of We're the very about enthusiastic THXXXX. progress XX:XX behind. We

This where that NASH alone. to are we we're this we're better very seems directionally tells times thought for said excited. would partner. that a the trial. early looking And it than We correct, like tolerated our committed is many, be. docetaxel is us still we report coming We've And THXXXX many

the are want capability there would discussion. be a in We from We point to available if it see and and trial. to partners where good some we're the fit are of resourcing committed view

don't of find one we're in need alternate sitting It's clinic. a to way committed in ready to that we a put the I finance sit NASH. finding highest the on unmet if we’ll this way, find medical one so We to X responsible to trial. would area, XX:XX for partner, the it, are So, and way see our on don't Phase program go shoulders

attending to update So, forward at the quarterly again next next much and looking report. Thank very the for you again. today thank you

Operator

concludes conference Thank participating. today's for you This XX:XX call.

You may now disconnect.

Theratechnologies (THTX) 13 Oct 212021 Q3 Earnings call transcript